GLP-1 vs GLP-2: What's the Difference, and Which One Are You On?

Is GLP-2 the same as GLP-1? Short answer: no

GLP-1 and GLP-2 share a name and a birthplace in the gut, and little else. GLP-1, short for glucagon-like peptide-1, slows digestion, turns down appetite and helps control blood sugar. Every drug in the Ozempic, Wegovy, Mounjaro and Zepbound family acts on it.

GLP-2 does a different job. It tells the cells lining your small intestine to grow. One GLP-2 drug is FDA-approved, and it treats a rare condition called short bowel syndrome, not weight or blood sugar.

Did I get confused, or am I on the wrong medication?

Most likely neither. The mix-up is easy to make: the names differ by one number, both hormones have FDA-approved drugs, and they were found together.

If you take semaglutide, tirzepatide or liraglutide for weight or blood sugar, you are on a GLP-1 drug. That is the right family for that goal. Nobody prescribes teduglutide, the GLP-2 drug, for weight loss. It is not studied or approved for that.

So the real question is not GLP-1 versus GLP-2. It is whether your GLP-1 drug and dose suit you, which is a question for the clinician who prescribes it.

What GLP-1 is, and which drugs count

GLP-1 is a hormone your gut releases after you eat. It nudges the pancreas to release insulin, slows how fast food leaves the stomach and signals fullness to the brain. That is why GLP-1 drugs both curb appetite and improve blood sugar.

• Semaglutide: Ozempic for type 2 diabetes, as a weekly shot or a daily pill. Since May 2026, the Ozempic pill is a newer tablet that replaced Rybelsus. Wegovy, as a shot or a pill, is the weight-management version.
• Tirzepatide: Mounjaro for type 2 diabetes, and Zepbound for weight management and for sleep apnea in adults with obesity. Tirzepatide also acts on a second gut hormone receptor, called GIP. It is grouped with GLP-1 drugs because of how it is used.
• Liraglutide: Victoza and its generics for type 2 diabetes. Saxenda, the weight-management version, is being discontinued by its maker.
• Orforglipron: Foundayo, a daily GLP-1 pill from Eli Lilly for weight management, approved in April 2026. It is not a peptide like the others.

If your prescription is one of these, you are on a GLP-1 drug. For starting doses and steps by drug, see the GLP-1 dosage guide.

What GLP-2 is, and why it isn't a weight-loss drug

GLP-2 is also a gut hormone, but its job is structural. It helps the tiny folds lining the small intestine grow, which gives the gut more surface to absorb food. It does not curb appetite or lower blood sugar the way GLP-1 does.

The one FDA-approved GLP-2 drug is teduglutide, sold as Gattex. It was approved in 2012 for adults and later for children 1 year and older. Its only use is short bowel syndrome in people who need nutrition through a vein because too much of their intestine is lost or not working.

A second GLP-2 drug, apraglutide, is still in trials for the same condition. The FDA asked for one more confirmatory trial in 2025. That trial, called STARS-2, started in June 2026 and is enrolling patients. Neither drug has any approved use for weight or diabetes.

Why do the names look so alike?

Both hormones are cut from the same larger protein, called proglucagon, inside gut cells known as L-cells. When you eat, those cells release GLP-1 and GLP-2 together.

Scientists found both when they decoded the proglucagon gene in the 1980s, so they got sibling names. They are molecular siblings with two different jobs, one about metabolism and one about gut structure. You did not misread anything.

Is a combined GLP-1 and GLP-2 drug coming?

Two different "dual" ideas get mixed up here. Tirzepatide is already a dual drug, but it pairs GLP-1 with GIP, not GLP-2.

A true GLP-1 and GLP-2 drug, dapiglutide, has had one small trial for obesity. The February 2026 study followed 54 adults for 12 weeks. On the higher dose, weight fell about 2% more than on placebo, a difference too small to rule out chance. The drug looked safe, and the authors want larger, longer studies.

That is a long way from a drug you could get. Nothing GLP-2-related is close to changing your options today.

Does GLP-2 have anything to do with perimenopause weight gain?

No. Short bowel syndrome usually follows major intestinal surgery or a condition present from birth. It has no known link to perimenopause, menopause or midlife weight change.

The weight shifts many women notice in their 40s and 50s are tied to falling estrogen and changing insulin sensitivity. That is territory where GLP-1 drugs have real evidence and GLP-2 drugs have none. For the bigger picture, see the perimenopause weight-loss medication overview.

So which GLP-1 is right for you?

With GLP-2 off the table, the real questions are the usual ones. Which GLP-1 fits your goals, what the dosing looks like, what side effects to expect, and what it costs.

For weight management, the main choices are semaglutide as Wegovy, tirzepatide as Zepbound, and the newer Foundayo pill. They differ in how they work and in typical results. What is a GLP-1, and how does it work explains the whole family first.